These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
25. Post-marketing surveillance of new drugs. Buckley EG J R Coll Gen Pract; 1987 Aug; 37(301):337-8. PubMed ID: 3448222 [No Abstract] [Full Text] [Related]
26. [Drug surveillance. Which methods? For which adverse effects? Application to teratogen monitoring]. Goujard J Therapie; 1985; 40(5):287-92. PubMed ID: 4095683 [No Abstract] [Full Text] [Related]
27. [Necessity and difficulties of quantitative drug monitoring]. Lagier G; Dally S; Vincens M; Castot A Therapie; 1983; 38(3):319-23. PubMed ID: 6612668 [No Abstract] [Full Text] [Related]
28. [A network of regional correspondents for studying undesirable effects]. Haramburu F; Péré JC; Begaud B; Albin H Therapie; 1985; 40(5):321-4. PubMed ID: 4095688 [No Abstract] [Full Text] [Related]
29. [Sensitivity and specificity of imputability criteria. Study and comparison of these efficacity indices for 7 methods]. Péré JC; Godin MH; Bégaud B; Haramburu F; Albin H Therapie; 1985; 40(5):307-12. PubMed ID: 4095687 [No Abstract] [Full Text] [Related]
31. Opening Pandora's pillbox: using modern information tools to improve drug safety. Gottlieb S Health Aff (Millwood); 2005; 24(4):938-48. PubMed ID: 16012136 [TBL] [Abstract][Full Text] [Related]
32. A study of sterilization containers. Kneedler JA; Gattas M J Healthc Mater Manage; 1988; 6(4):24-8, 30. PubMed ID: 10287651 [TBL] [Abstract][Full Text] [Related]
33. Adverse drug reaction monitoring: doing it the French way. Moore N; Biour M; Paux G; Loupi E; Begaud B; Boismare F; Royer RJ Lancet; 1985 Nov; 2(8463):1056-8. PubMed ID: 2865527 [No Abstract] [Full Text] [Related]
34. Postmarketing studies of drug efficacy: when must they be randomized? Strom BL; Miettinen OS; Melmon KL Clin Pharmacol Ther; 1983 Jul; 34(1):1-7. PubMed ID: 6861430 [No Abstract] [Full Text] [Related]
35. The computerized on-line Medicaid pharmaceutical analysis and surveillance system: a new resource for postmarketing drug surveillance. Strom BL; Carson JL; Morse ML; LeRoy AA Clin Pharmacol Ther; 1985 Oct; 38(4):359-64. PubMed ID: 3899458 [No Abstract] [Full Text] [Related]
36. Techniques of postmarketing surveillance. An overview. Carson JL; Strom BL Med Toxicol; 1986; 1(4):237-46. PubMed ID: 3537618 [No Abstract] [Full Text] [Related]
37. Postmarketing surveillance of adverse drug reactions: problems and solutions. Lortie FM CMAJ; 1986 Jul; 135(1):27-32. PubMed ID: 3719483 [TBL] [Abstract][Full Text] [Related]
38. Adverse drug reactions and reporting. Witte R Clin J Oncol Nurs; 2000; 4(4):181, 184. PubMed ID: 11261100 [No Abstract] [Full Text] [Related]
39. Postmarketing surveillance methodologies. Edlavitch SA Drug Intell Clin Pharm; 1988 Jan; 22(1):68-78. PubMed ID: 3280280 [TBL] [Abstract][Full Text] [Related]
40. [Drug by drug imputation of adverse effects in drug monitoring. Attempted comparison of different methods]. Lagier G; Vincens M; Lefebure B; Frelon JH Therapie; 1983; 38(3):295-302. PubMed ID: 6612666 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]